Barclays raised the firm’s price target on Abbott (ABT) to $158 from $149 and keeps an Overweight rating on the shares. The firm increased earnings estimates for Abbott’s 2025, “despite significant headwinds” from currency and taxes. It continues to view the company as a “high-quality diversified MedTech growth story.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $135 from $130 at Stifel
- Abbott price target raised to $138 from $135 at Bernstein
- Abbott price target raised to $148 from $146 at UBS, shares remain undervalued
- Abbott Laboratories Reports Strong 2024 Financial Results
- Abbott price target raised to $140 from $139 at BTIG